Compositions, Methods and/or Devices For Prevention and/or Treatment Of Dry Eye Disorders

• US 20150157591A1
• Filed: 07/09/2013
• Published: 06/11/2015
• Est. Priority Date: 07/09/2012
• Status: Active Grant

• Current Assignee: Brien Holden Vision Institute
• Original Assignee: Brien Holden Vision Institute
• Inventors: Zhu, Hua, Flanagan, Judith Louise
• Granted Patent: US 10,004,714 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/568 substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
• CPC Class Codes: A61K 31/5685 having an oxo group in position 17, e.g. androsterone
• CPC Class Codes: A61K 31/7052 having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/06 Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• CPC Class Codes: A61K 47/24 containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61K 47/44 Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61L 12/12 Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone A61L12/10 takes precedence
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/04 Artificial tears; Irrigation solutions

Abstract

The present disclosure relates to compositions, methods and devices for treating, reducing or preventing one or more eye disorders, particularly dry eye disorders, in a subject by administering an amount of one or more fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity while permitting bacterial growth or without substantially altering the dynamic microbial community of the eye. Typically, the fatty acids and/or fatty acid esters are C₈ to C₁₆ fatty acids and/or fatty acid esters.

Claims

1-23. -23. (canceled)

24. A method for treating or preventing a dry eye disorder in a subject by administering to the subject'"'"'s eye a composition with an amount of one or more C₈ to C₁₆ fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity without substantially altering the dynamic microbial community of the subject'"'"'s eye to which the composition has been administered;

wherein the amount of one or more C₆ to C₁₆ fatty acids and/or fatty acid esters is in a concentration of between 2.5 μ

g/ml to 15 μ

g/ml in the composition.

25. A method of claim 24, wherein the fatty acids and/or fatty acid esters are C₁₀ to C₁₄ fatty acids and/or fatty acid esters

28. A method according to claim 24, wherein the fatty acid and/or fatty acid ester is glycerol monolaurate, lauric acid or a combination thereof.

29. A method according to claim 24, further comprising administering a therapeutically effective amount of androgen.

30. A method of claim 29, wherein the androgen is selected from one or more of the following:

dehydroepiandrosterone (DHEA), androsterone, testosterone and dihydrotestosterone.

31. A method according to claim 24, further comprising administering a therapeutically effective amount of an anti-inflammatory agent.

32. A method of claim 31, wherein the anti-inflammatory agent is selected from one or more of the following:

azithromycin, cyclosporine A, omega-3 fatty acids and transforming growth factor beta (TGF-β

).

26-27. -27. (canceled)

33-34. -34. (canceled)

39. (canceled)

41. The method of claim 35, wherein the amount of lauric acid included in the eye drops or associated with the contact lenses is in a concentration of about 2.5 μ

g/ml to 15 μ

g/ml.

41-45. -45. (canceled)

46. The method according to one or more of the above method claims, wherein the amount of one or more C₈ to C₁₆ fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity in the subject'"'"'s eye while permitting bacterial growth in the subject'"'"'s eye.